Fig 1: The potential biomarkers for the prognosis of HCCA. Kaplan-Meier survival curves for HCC patients with different expression levels of CHST4, SLC22A8, and STC2. B. ROC curves of CHST4, SLC22A8, and STC2 expression for predicting overall survival of HCC patients. C. Kaplan-Meier survival curves for HCC patients with different expression levels of hsa-miR-326 and hsa-miR-21. D. ROC curves of hsa-miR-326 and hsa-miR-21 expression for predicting overall survival of HCC patients. ROC, receiver operating characteristic; AUROC, area under the ROC curve.
Fig 2: Clinical significance of CHST4, SLC22A8, STC2, hsa-miR-326, and hsa-miR-21A. Typical images of IHC staining for SLC22A8, CHST4, and STC2 in HCC patients with distinct prognosis. Scale bar, 50 μm. B. Clinical validation of the prognostic significance of SLC22A8, CHST4, and STC2. Upper: the significance for predicting recurrence; lower: the significance for predicting overall survival. C. Clinical validation of the prognostic significance of has-miR-326 and has-miR-21. Upper: the significance for predicting recurrence; lower: the significance for predicting overall survival. D. Expression status of selected mRNAs/miRNAs between HCC and paired adjacent normal liver tissues. The average expression levels of indicated mRNAs/miRNAs in normal tissues were set as 1.0, and the expression levels of mRNAs/miRNAs in HCC tissues were calculated as HCC/normal to determine the FC in expression. IHC, immunohistochemistry; FC, fold change.
Supplier Page from Abcam for Anti-OAT3 antibody